• Education

    University of Bern, 1989

  • Residencies

    Indiana University School of Medicine, Internal Medicine, 1996

  • Fellowships

    Memorial Sloan-Kettering Cancer Center, Hematology-Oncology, 2000

  • Academic Title

    Professor

  • Languages

    French

    German

    Italian

Where I see patients (2)

    My reviews

    4.8

    Overall Experience
    99 Ratings
    Explained things in a way that was easy to understand
    99 Ratings
    Did the doctor pay attention to your concerns
    99 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    96 Ratings
    Knew the important information about your medical history
    97 Ratings
    The provider showed respect for what you had to say
    98 Ratings
    The provider spent enough time with me
    98 Ratings
    Decorative Caduceus

    Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in ...

    A dose limiting toxicity (DLT) will be defined as any predetermined adverse events occurring during Cycle 1 when association to therapy that is part of this study is related or possibly related

    Recruiting

    Decorative Caduceus

    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects...

    Treatment-emergent adverse events will be a primary outcome measure for the following groups: Phase 1 Dose Exploration Part 1 monotherapy Phase 1 Dose Expansion Part 2 monotherapy Phase 1 combination arm with AMG 510 and anti P...

    Recruiting

    Decorative Caduceus

    TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

    Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab.

    Recruiting

    Decorative Caduceus

    Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

    Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values or vital signs for RMC-5552 monotherapy

    Recruiting

    Decorative Caduceus

    9-ING-41 in Patients With Advanced Cancers

    The standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 4.03 will be conduced at each protocol-specified timepoint.

    Recruiting

    Decorative Caduceus

    AO-176 in Multiple Solid Tumor Malignancies

    Evaluate the safety of AO-176 measured by the number adverse events, serious adverse events and lab abnormalities.

    Recruiting

    Decorative Caduceus

    A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Sol...

    Identify nature and frequency of dose limiting toxicities

    Recruiting

    Decorative Caduceus

    A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in H...

    Best overall response rate as assessed by the investigator by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in patients with advanced prostate cancer).

    Recruiting

    Decorative Caduceus

    Study of ORIC-101 in Combination With Anticancer Therapy

    RP2D as determined by 3+3 dose escalation design

    Recruiting

    Share